Abstract 226P
Background
Urothelial carcinoma (UC) has a highly complex genomic landscape. With the spread of immunotherapy, accurate stratification strategies are needed. As cancer tissues are now frequently screened for specific sets of mutations, a large number of samples has become available for analysis. Classification of patients with similar mutation profiles may help identifying subgroups of patients outcomes. However, classification based on somatic mutations is challenging due to the sparseness and heterogeneity of the data.
Methods
A retrospective study was performed to identify the prognosis-related somatic mutations from 192 UC in The Cancer Genome Atlas (TCGA) database. Cox regression were performed to screen out prognostic genes.
Results
A total of 176 genes were related with immuno-survival. Then, a stepwise multivariate Cox regression analysis was performed, and 14 gene were selected to establish a predictive model. Compared with the wildtype group, the patients with mutated signature had unfavorable to prognosis (p<0.001). ROC curve analysis demonstrated the predictive ability for 1-, 3-, 5-, and 10-year OS, with areas under the curve (AUCs) of 0.7684, 0.667,0.619 and 0.647, respectively. In mutated signature cohorts, the five most frequently mutated genes were TP53 (50%), KMT2D (43%), LRP1B (33%), PER1 (33%), and RNF213 (33%). Dissimilarly, the five most frequently mutated genes were TP53 58%), ARID1A (29%), KMT2D (29%), RNF213 (27%), and KDM6A (26%) in wildtype cohorts, which may imply that different characteristic states have different molecular mechanisms.
Conclusions
These data underline the potential value of using somatic mutations to accurately stratify UC patients into clinically actionable subgroups. This model could reduce overtreatment in UC patients with mutations.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract